Hepatitis B virus messenger RNAs (HBV mRNA)

Hepatitis B virus (HBV) messenger RNAs (mRNAs) are essential viral transcripts that encode all proteins necessary for the virus's lifecycle, including the surface antigen (HBsAg), core protein, and polymerase [7.2.1]. Additionally, the pregenomic RNA (pgRNA) serves as the template for reverse transcription to produce new viral DNA [8.2.3]. Because the HBV genome consists of overlapping open reading frames, all viral mRNAs share common sequences, particularly in highly conserved regions across different genotypes [10.2.1]. Targeting these conserved regions with RNA interference (RNAi) or antisense oligonucleotides (ASOs) allows for the simultaneous degradation of all HBV mRNA species, effectively silencing viral protein production and replication [10.1.2]. Therapeutic agents like ARB-1467 and JNJ-3989 utilize multiple siRNA triggers to target three or two conserved genomic regions, respectively, ensuring broad efficacy and reducing the risk of viral escape [8.2.1, 10.2.2]. By significantly lowering the levels of viral antigens, these therapies aim to restore the host's immune response and achieve a functional cure for chronic hepatitis B [7.1.2]. Clinical development often involves combination with nucleos(t)ide analogues to maximize suppression of viral markers [7.1.4]. Notable safety considerations include transient elevations in liver enzymes (ALT flares), which may reflect the restoration of the host immune response against infected hepatocytes [10.1.3].

Other names

Hepatitis B virus RNAHBV transcriptsHBV pregenomic RNAHBV pgRNAHBV genomic RNAHepatitis B virus messenger RNAs in three conserved genomic regions

RNA interference (RNAi) and antisense-mediated degradation (RNase H) leading to the cleavage and depletion of all viral mRNA transcripts, thereby inhibiting viral protein synthesis and replication.